0 results

    ABIONYX Pharma

    ABIONYX Pharma (formerly Cerenis Therapeutics) is dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment.

    The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno oncology and chemotherapy.

      Related News

        SofinnovaCapital

        The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.

        SofinnovaMD Start

        The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.

        SofinnovaCrossover

        The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.

        SofinnovaIndustrial Biotech

        Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.

        SofinnovaTelethon

        The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.

        SofinnovaDigital Medicine

        The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.

        SofinnovaBiovelocita

        The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.